AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Intercept Pharmaceuticals Inc (NASDAQ:ICPT)
-- USD
0.000 0.000%| Previous Close (in USD) | -- |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 21.860/8.822 |
| EBITDA (in USD) | -54.718M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -1.09 |
| Total Assets (in USD) | 553.711M |
|---|---|
| Total Liabilities (in USD) | 460.634M |
| Revenue TTM (in USD) | 317.684M |
| Cash (in USD) | 50.517M |
| Market Cap (in USD) | 794.694 M |
| Revenue Per Share TTM | 7.620 |
| Gross Profit TTM (in USD) | 284.726M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Intercept Pharmaceuticals Inc
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..
Employees: 341
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Jerome B. Durso | Pres, CEO & Director | 1968 |
| 2. | Mr. Andrew Saik | Chief Financial Officer | 1969 |
| 3. | Mr. Rocco Venezia | Chief Accounting Officer & Treasurer | 1976 |
| 4. | Mr. Jared M. Freedberg J.D. | Gen. Counsel | 1968 |
| 5. | Dr. M. Michelle Berrey M.D., M.P.H., MPH. | Pres of R&D and Chief Medical Officer | 1967 |
| 6. | Mr. Nareg Sagherian | Exec. Director of Global Investor Relations | NA |
| 7. | Mr. David Ford | Chief HR Officer | 1970 |
| 8. | Dr. Mark Pruzanski M.D. | Founder, Advisor & Director | 1968 |
| 9. | Ms. Linda M. Richardson | Exec. VP & Chief Commercial Officer | 1964 |
| 10. | Paul Nitschmann | Sr. VP of Regulatory Affairs | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -174.858M | -91.426M | -274.88M | -344.681M | -309.242M |
| Minority Interest | - | - | - | - | - |
| Net Income | 115.174M | -145.022M | -324.23M | -391.052M | -309.242M |
| Selling General Administrative | 176.303M | 230.855M | 332.493M | 317.418M | 255.474M |
| Gross Profit | 284.726M | 360.368M | 307.368M | 247.79M | 177.285M |
| Reconciled Depreciation | 0.592M | 2.978M | 3.118M | 3.663M | 4.582M |
| Ebit | -68.216M | -55.759M | -216.61M | -312.427M | -283.301M |
| Ebitda | -61.695M | -53.604M | -212.196M | -303.537M | -278.719M |
| Depreciation And Amortization | 6.521M | 2.155M | 4.414M | 8.89M | 4.582M |
| Operating Income | -68.216M | -55.759M | -216.61M | -312.427M | -285.49M |
| Other Operating Expenses | 353.926M | 419.227M | 529.3M | 564.429M | 465.294M |
| Interest Expense | 21.385M | 54.419M | 48.054M | 41.144M | 30.523M |
| Tax Provision | - | - | - | - | - |
| Interest Income | - | - | - | 41.144M | 30.523M |
| Net Interest Income | -21.385M | -54.419M | -48.054M | -41.144M | -30.523M |
| Income Tax Expense | -290.032M | 53.596M | 49.35M | 46.371M | 6.771M |
| Total Revenue | 285.71M | 363.468M | 312.69M | 252.002M | 179.804M |
| Total Operating Expenses | 352.942M | 416.127M | 523.978M | 560.217M | 462.775M |
| Cost Of Revenue | 0.984M | 3.1M | 5.322M | 4.212M | 2.519M |
| Total Other Income Expense Net | -106.642M | -35.667M | -58.27M | -32.254M | 6.771M |
| Net Income From Continuing Ops | -174.858M | -91.426M | -274.88M | -344.681M | -309.242M |
| Net Income Applicable To Common Shares | 221.816M | -91.426M | -274.88M | -344.681M | -309.242M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Total Assets | 553.711M | 527.023M | 580.489M | 754.886M | 509.167M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 22.356M | 25.286M | 27.022M | 25.924M | 20.571M |
| Total Liab | 460.634M | 710.985M | 747.342M | 703.33M | 490.037M |
| Total Stockholder Equity | 93.077M | -183.962M | -166.853M | 51.556M | 19.13M |
| Other Current Liab | 106.274M | 8.952M | 8.942M | 6.039M | 18.328M |
| Common Stock | 0.042M | 0.03M | 0.033M | 0.033M | 0.03M |
| Capital Stock | 0.042M | 0.03M | 0.033M | 0.033M | 0.03M |
| Retained Earnings | -2136.888M | -2489.772M | -2398.346M | -2123.466M | -1778.785M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 15.235M | 16.095M | 15.123M | 16.331M |
| Cash | 50.517M | 84.709M | 58.151M | 70.055M | 436.16M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 230.077M | 166.817M | 179.076M | 162.005M | 114.205M |
| Current Deferred Revenue | - | 136.691M | 138.292M | 130.535M | 1.621M |
| Net Debt | 282.156M | 462.501M | 517.363M | 468.479M | -64.91M |
| Short Term Debt | 109.569M | 3.042M | 7.248M | 6.456M | 82.491M |
| Short Long Term Debt | 109.569M | - | - | - | - |
| Short Long Term Debt Total | 332.673M | 547.21M | 575.514M | 538.534M | 371.25M |
| Other Stockholder Equity | 2238.179M | 2308.653M | 2233.937M | 2176.133M | 1800.144M |
| Property Plant Equipment | 7.449M | 11.996M | 15.353M | 13.664M | 10.411M |
| Total Current Assets | 540.127M | 502.292M | 477.17M | 721.315M | 482.425M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 435.049M | 334.98M | 411.516M | 582.567M | 392.912M |
| Net Receivables | 26.862M | 47.617M | 41.549M | 38.044M | 25.694M |
| Long Term Debt | 223.104M | 539.782M | 560.582M | 532.078M | 371.25M |
| Inventory | 6.462M | 8.619M | -68.571M | 8.462M | 7.108M |
| Accounts Payable | 14.234M | 18.132M | 24.594M | 18.975M | 11.765M |
| Accumulated Other Comprehensive Income | -8.256M | -2.873M | -2.477M | -1.144M | -2.259M |
| Non Currrent Assets Other | 12.597M | 15.235M | 84.666M | 15.123M | 16.331M |
| Non Current Assets Total | 13.584M | 24.731M | 103.319M | 33.571M | 26.742M |
| Capital Lease Obligations | - | 7.428M | 14.932M | 6.456M | - |
| Long Term Debt Total | 223.104M | 539.782M | 560.582M | 532.078M | 371.25M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -100.816M | 71.123M | 166.708M | -187.852M | -47.903M |
| Total Cashflows From Investing Activities | 261.849M | 70.726M | 162.817M | -188.988M | -48.07M |
| Total Cash From Financing Activities | -267.316M | 1.118M | -0.693M | 457.519M | 263.545M |
| Net Income | -174.858M | -91.426M | -274.88M | -344.681M | -309.242M |
| Change In Cash | -38.549M | 28.755M | -9.126M | 31.532M | -26.765M |
| Begin Period Cash Flow | 94.409M | 65.654M | 74.78M | 43.248M | 70.013M |
| End Period Cash Flow | 55.86M | 94.409M | 65.654M | 74.78M | 43.248M |
| Total Cash From Operating Activities | -26.78M | -41.639M | -170.026M | -236.613M | -240.714M |
| Depreciation | 0.592M | 2.978M | 3.118M | 3.663M | 4.582M |
| Other Cashflows From Investing Activities | 363.233M | - | - | -187.852M | -47.903M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | 0.602M | 0.231M | -0.269M | -1.354M | -3.628M |
| Sale Purchase Of Stock | 1.684M | -75.825M | 1.301M | 236.253M | 265.725M |
| Other Cashflows From Financing Activities | 1.092M | 115.072M | -0.693M | 230.259M | 2.183M |
| Capital Expenditures | 0.568M | 0.397M | 3.891M | 1.136M | 0.167M |
| Change In Working Capital | 21.917M | -14.417M | 1.999M | 19.331M | -2.847M |
| Other Non Cash Items | 103.68M | 39.114M | 34.646M | 26.712M | 15.573M |
| Free Cash Flow | -27.348M | -42.036M | -173.917M | -237.749M | -240.881M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | AB Merger Arbitrage S1 USD | 2 years ago | 480168 |
| 2. | Fidelity® Small Cap Index | 2 years ago | 379654 |
| 3. | Pictet Biopharmaceutical Mother | 3 years ago | 352457 |
| 4. | AB Event Driven S1 USD | 2 years ago | 276382 |
| 5. | Jupiter Merian Glb Eq AbsRet I USD Acc | 2 years ago | 261138 |
| 6. | Fidelity® Extended Market Index | 2 years ago | 196331 |
| 7. | Fuller & Thaler Behavrl Micro-Cap Core | 2 years ago | 193940 |
| 8. | TIAA-CREF Quant Small-Cap Equity Instl | 2 years ago | 172270 |
| 9. | NT R2000 Growth Index Fund - NL | 2 years ago | 121653 |
| 10. | NT R2000 Index Fund - NL | 2 years ago | 116478 |
| 11. | Vanguard Growth & Income Inv | 2 years ago | 113000 |
| 12. | Schwab Small Cap Index | 2 years ago | 94863 |
| 13. | Old Mutual Global Equity R | 2 years ago | 93635 |
| 14. | NT R2000 Index Fund - DC - NL - 2 | 2 years ago | 92082 |
| 15. | BlackRock Extended Mkt Composite | 2 years ago | 87435 |
| 16. | Northern Trust Russell 2000 Growth Index | 2 years ago | 85826 |
| 17. | NT R2000 Growth Index Fund - L | 2 years ago | 85826 |
| 18. | TIAA-CREF Equity Index Instl | 2 years ago | 80009 |
| 19. | BlackRock Extended Equity Market K | 2 years ago | 75386 |
| 20. | Russell 2000 Index Non-Lendable Fund E | 2 years ago | 72082 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 2 years ago | 4212820 |
| 2. | State Street Corporation | 2 years ago | 3197810 |
| 3. | UBS Group AG | 2 years ago | 2999188 |
| 4. | Magnetar Financial LLC | 2 years ago | 2407209 |
| 5. | Eckert Corp | 2 years ago | 2203295 |
| 6. | Deerfield Management Co | 2 years ago | 2077893 |
| 7. | Vanguard Group Inc | 2 years ago | 2071232 |
| 8. | Jefferies Financial Group Inc | 2 years ago | 2000000 |
| 9. | AllianceBernstein L.P. | 2 years ago | 1542896 |
| 10. | Rockefeller Capital Management L.P. | 2 years ago | 1037763 |
| 11. | Goldman Sachs Group Inc | 2 years ago | 1019073 |
| 12. | Renaissance Technologies Corp | 2 years ago | 825800 |
| 13. | Geode Capital Management, LLC | 2 years ago | 793321 |
| 14. | D. E. Shaw & Co LP | 2 years ago | 791335 |
| 15. | Cnh Partners, LLC | 2 years ago | 734970 |
| 16. | Samsara BioCapital, LLC | 2 years ago | 640688 |
| 17. | Morgan Stanley - Brokerage Accounts | 2 years ago | 576774 |
| 18. | HSBC Holdings PLC | 2 years ago | 456623 |
| 19. | Acadian Asset Management LLC | 2 years ago | 409183 |
| 20. | Bank of America Corp | 2 years ago | 402359 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...